Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.07
Nov 18 • 3:59 PM ET Dollar change-0.79 Percentage change(-27.62%)
Aftermarket Close
2.09
Aftermarket • 7:30 PM ET Dollar change+0.02 Percentage change(0.78%)
Nov 18, 11:02 AMCEO Cunningham's abrupt GeneDx exit sinks Quanterix 25% in regular hours
Index
RUT
Market Cap
98.28M
Enterprise Value
52.28M
Income
-111.18M
Sales
148.15M
Book/sh
4.62
Cash/sh
1.63
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
450
IPO
Dec 07, 2017
P/E
-
Forward P/E
-
PEG
-
P/S
0.66
P/B
0.45
P/C
1.27
P/FCF
-
EV/EBITDA
-
EV/Sales
0.35
Quick Ratio
2.22
Current Ratio
3.09
Debt/Eq
0.14
LT Debt/Eq
0.11
Option/Short
Yes / Yes
EPS (ttm)
-2.36
EPS next Y
-1.44
EPS next Q
-0.37
EPS this Y
9.36%
EPS next Y
36.66%
EPS next 5Y
25.05%
EPS past 3/5Y
2.27% -18.72%
Sales past 3/5Y
9.59% 9.97%
EPS Y/Y TTM
-1.29%
Sales Y/Y TTM
13.78%
EPS Q/Q
37.39%
Sales Q/Q
-13.07%
Insider Own
11.73%
Insider Trans
1.88%
Inst Own
63.01%
Inst Trans
-18.95%
ROA
-29.86%
ROE
-41.65%
ROIC
-45.70%
Gross Margin
41.70%
Oper. Margin
-60.90%
Profit Margin
-75.05%
SMA20
-28.96%
SMA50
-31.95%
SMA200
-42.67%
Trades
Shs Outstand
47.45M
Shs Float
41.91M
52W High
8.77 -76.40%
52W Low
2.15 -3.72%
Volatility
11.45% 8.99%
ATR (14)
0.29
RSI (14)
31.88
Beta
1.01
Rel Volume
5.48
Avg Volume
646.45K
Volume
3,539,894
Perf Week
-31.46%
Perf Month
-23.90%
Perf Quarter
-33.65%
Perf Half Y
-17.86%
Perf YTD
-67.45%
Perf Year
-63.17%
Perf 3Y
-90.78%
Perf 5Y
-95.54%
Perf 10Y
-
Prev Close
2.86
Price
2.07
Change %
-27.62%
Consensus
Hold
Avg. Price Target
$3.33
Implied Upside
+60.9%
Analysts6incl. previous ratings
Rating Distribution3 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 11, 2025Downgrade
CCanaccord Genuity
Buy → Hold$5+141.5%
Feb 01, 2024Initiated
BNS logoBScotiabank
Sector Outperform$30+1,349.3%
Sep 25, 2023Upgrade
CCanaccord Genuity
Hold → Buy$25 → $32+1,445.9%
Aug 08, 2023Upgrade
SSVB Securities
Market Perform → Outperform$30+1,349.3%
May 23, 2023Upgrade
GS logoGGoldman
Neutral → Buy$13 → $27+1,204.3%
Aug 15, 2022Downgrade
CCanaccord Genuity
Buy → Hold$40 → $12+479.7%
Aug 09, 2022Downgrade
SSVB Leerink
Outperform → Mkt Perform$35 → $15+624.6%
Aug 09, 2022Downgrade
CCowen
Outperform → Market Perform$38 → $18+769.6%
Mar 02, 2022Upgrade
GS logoGGoldman
Sell → Neutral$40+1,832.4%
Oct 15, 2021Resumed
CCowen
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DONNELLY WILLIAM PDirectorAug 13 '26Buy2.9372,245211,67899,400Aug 14 04:01 PM
DONNELLY WILLIAM PDirectorAug 12 '26Buy2.7527,15574,67627,155Aug 14 04:01 PM
Meadows BenjaminChief Commercial OfficerMay 12 '26Buy2.773,5009,6953,500Jun 12 05:32 PM
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.
Executive ChairMr. William P. Donnelly
Co-Founder & Chairman of Scientific Advisory BoardDr. David R. Walt Ph.D.
PresidentMr. Everett V. Cunningham
CFO & TreasurerMr. Jason Faessler
Chief Operating OfficerMr. Anthony Catalano